BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Younossi ZM, Paik JM, Al Shabeeb R, Golabi P, Younossi I, Henry L. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease? Hepatology 2022;76:1423-37. [PMID: 35363908 DOI: 10.1002/hep.32499] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 26.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen J, Mao X, Deng M, Luo G. Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD. Eur J Gastroenterol Hepatol 2023;35:394-401. [PMID: 36695773 DOI: 10.1097/MEG.0000000000002497] [Reference Citation Analysis]
2 Adams LA. Cardiovascular disease in metabolic-associated fatty liver disease. Curr Opin Endocrinol Diabetes Obes 2023;30:81-6. [PMID: 36779252 DOI: 10.1097/MED.0000000000000803] [Reference Citation Analysis]
3 Aimuzi R, Xie Z, Qu Y, Jiang Y, Luo K. Associations of urinary organophosphate esters metabolites and diet quality with nonalcoholic/metabolic dysfunction-associated fatty liver diseases in adults. Ecotoxicol Environ Saf 2023;254:114720. [PMID: 36889207 DOI: 10.1016/j.ecoenv.2023.114720] [Reference Citation Analysis]
4 van Kleef LA, de Knegt RJ, Brouwer WP. Reply. Hepatology 2023;77:E45-6. [PMID: 36057078 DOI: 10.1002/hep.32718] [Reference Citation Analysis]
5 van Kleef LA, de Knegt RJ, Brouwer WP. Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality. Hepatology 2023;77:942-8. [PMID: 35776631 DOI: 10.1002/hep.32642] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
6 Hsu CL, Wang Y, Duan Y, Chu H, Hartmann P, Llorente C, Zhou R, Schnabl B. Differences in Bacterial Translocation and Liver Injury in Ethanol Versus Diet-Induced Liver Disease. Dig Dis Sci 2023. [PMID: 36807831 DOI: 10.1007/s10620-023-07860-1] [Reference Citation Analysis]
7 Taru MG, Neamti L, Taru V, Procopciuc LM, Procopet B, Lupsor-Platon M. How to Identify Advanced Fibrosis in Adult Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Using Ultrasound Elastography-A Review of the Literature and Proposed Multistep Approach. Diagnostics (Basel) 2023;13. [PMID: 36832276 DOI: 10.3390/diagnostics13040788] [Reference Citation Analysis]
8 Chen Z, Chen M, Zeng P, Yang X, Li Q. Association of aspirin with all-cause and cardiocerebrovascular mortality in patients with metabolic associated fatty liver disease. Scand J Gastroenterol 2023;:1-7. [PMID: 36799202 DOI: 10.1080/00365521.2023.2179864] [Reference Citation Analysis]
9 Fan Y, Zhang Y, Chen C, Ying Z, Su Q, Li X, Chen Y. Fasting serum fructose is associated with metabolic dysfunction-associated fatty liver disease: A prospective study. Hepatol Res 2023. [PMID: 36745152 DOI: 10.1111/hepr.13888] [Reference Citation Analysis]
10 Xie ZQ, Li HX, Wang BK, Yang ZM, Zhang ZY, Tan WL, Li WX, Wang QB, Yang L, Zhuang HK, Tang CW, Shang CZ, Chen YJ. Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study. Eur J Intern Med 2023:S0953-6205(23)00034-1. [PMID: 36754655 DOI: 10.1016/j.ejim.2023.01.029] [Reference Citation Analysis]
11 Gofton C, Upendran Y, Zheng MH, George J. MAFLD: How is it different from NAFLD? Clin Mol Hepatol 2023;29:S17-31. [PMID: 36443926 DOI: 10.3350/cmh.2022.0367] [Reference Citation Analysis]
12 Zhu Y, Wang E, Zhao S, Han D, Zhao Y, Chen H, Zhu J, Han T, Bai Y, Lou Y, Zhang Y, Yang M, Zuo L, Fan J, Chen X, Jia J, Wu W, Ren W, Bai T, Ma S, Xu F, Tang Y, Han Y, Zhao J, Qi X, Li J, Du X, Chen D, Liu L. Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study. Front Oncol 2022;12:983554. [PMID: 36776366 DOI: 10.3389/fonc.2022.983554] [Reference Citation Analysis]
13 Yoo TK, Lee MY, Kim SH, Zheng MH, Targher G, Byrne CD, Sung KC. Comparison of cardiovascular mortality between MAFLD and NAFLD: A cohort study. Nutr Metab Cardiovasc Dis 2023:S0939-4753(23)00024-8. [PMID: 36746687 DOI: 10.1016/j.numecd.2023.01.013] [Reference Citation Analysis]
14 Liao Y, Wang L, Liu F, Zhou Y, Lin X, Zhao Z, Xu S, Tang D, Jiao Y, Yang L, Yu W, Gao P. Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis. Front Endocrinol (Lausanne) 2023;14:1078149. [PMID: 36761200 DOI: 10.3389/fendo.2023.1078149] [Reference Citation Analysis]
15 Tang SY, Tan JS, Pang XZ, Lee GH. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact. World J Gastroenterol 2023; 29(3): 549-560 [PMID: 36688021 DOI: 10.3748/wjg.v29.i3.549] [Reference Citation Analysis]
16 Torres L, Schuch A, Longo L, Valentini BB, Galvão GS, Luchese E, Pinzon C, Bartels R, Álvares-da-Silva MR. New FIB-4 and NFS cutoffs to guide sequential non-invasive assessment of liver fibrosis by magnetic resonance elastography in NAFLD. Ann Hepatol 2023;28:100774. [PMID: 36280013 DOI: 10.1016/j.aohep.2022.100774] [Reference Citation Analysis]
17 Muthiah M, Ng CH, Chan KE, Fu CE, Lim WH, Tan DJH, Nah B, Kong G, Xiao J, Yong JN, Tan B, Syn N, Wang JW, Sayed N, Tan E, Chew NW, Dan YY, Siddiqui MS, Sanyal AJ, Noureddin M. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis. Ann Hepatol 2023;28:100762. [PMID: 36182031 DOI: 10.1016/j.aohep.2022.100762] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Zhang W, Wang X, Huang J, Wang S, Yao Q, Li H. Healthy Eating Index-2015 in relation to risk of metabolic dysfunction-associated fatty liver disease among US population: National Health and Nutrition Examination Survey 2017-2018. Front Nutr 2022;9:1043901. [PMID: 36712521 DOI: 10.3389/fnut.2022.1043901] [Reference Citation Analysis]
19 Yi Y, Wang C, Ding Y, He J, Lv Y, Chang Y. Diet was less significant than physical activity in the prognosis of people with sarcopenia and metabolic dysfunction-associated fatty liver diseases: Analysis of the National Health and Nutrition Examination Survey III. Front Endocrinol (Lausanne) 2023;14:1101892. [PMID: 36909338 DOI: 10.3389/fendo.2023.1101892] [Reference Citation Analysis]
20 Yi J, Wang L, Guo J, Ren X. Novel metabolic phenotypes for extrahepatic complication of nonalcoholic fatty liver disease. Hepatol Commun 2023;7:e0016. [PMID: 36633488 DOI: 10.1097/HC9.0000000000000016] [Reference Citation Analysis]
21 Gau SY, Hsiao YP, Liao WC, Ma KS, Wu MC. Risk of liver dysfunction and non-alcoholic fatty liver diseases in people with hidradenitis suppurativa: A systematic review and meta-analysis of real-world evidences. Front Immunol 2022;13:959691. [PMID: 36591267 DOI: 10.3389/fimmu.2022.959691] [Reference Citation Analysis]
22 Yu MW, Lin CL, Liu CJ, Wu WJ, Hu JT, Huang YW. Metabolic-Associated Fatty Liver Disease, Hepatitis B Surface Antigen Seroclearance, and Long-Term Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. Cancers (Basel) 2022;14. [PMID: 36497492 DOI: 10.3390/cancers14236012] [Reference Citation Analysis]
23 Wong R, Fortune BE. The Shift from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease. Clin Liver Dis (Hoboken) 2022;20:157-61. [PMID: 36447906 DOI: 10.1002/cld.1250] [Reference Citation Analysis]
24 Hari A. Ultrasound-Based Diagnostic Methods: Possible Use in Fatty Liver Disease Area. Diagnostics (Basel) 2022;12. [PMID: 36428882 DOI: 10.3390/diagnostics12112822] [Reference Citation Analysis]
25 Kawada T. Nonalcoholic Fatty Liver Disease Without Metabolic-Associated Fatty Liver Disease and Metabolic Syndrome. Clin Gastroenterol Hepatol 2022:S1542-3565(22)01049-7. [PMID: 36372370 DOI: 10.1016/j.cgh.2022.10.034] [Reference Citation Analysis]
26 García-Compeán D, Jiménez-Rodríguez AR. NAFLD VS MAFLD. The evidence-based debate has come. Time to change? Ann Hepatol 2022;27:100765. [PMID: 36179795 DOI: 10.1016/j.aohep.2022.100765] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Attia D, Gomaa A, Abdel Alem S. Letter to the editor: Pitfalls in the outcome differences between NAFLD and MAFLD. Hepatology 2022;76:E100. [PMID: 35532891 DOI: 10.1002/hep.32563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Henry L, Paik JM, Younossi ZM. Reply. Hepatology 2022;76:E102-3. [PMID: 35532942 DOI: 10.1002/hep.32565] [Reference Citation Analysis]
29 van Kleef LA, de Knegt RJ. The transition from NAFLD to MAFLD: One size still does not fit all-Time for a tailored approach? Hepatology 2022;76:1243-5. [PMID: 35503710 DOI: 10.1002/hep.32552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Fouad Y, Abdel Dayem WA, Mehrez M. Letter to the editor: Apples should be compared with apples. Hepatology 2022;76:E101. [PMID: 35532941 DOI: 10.1002/hep.32564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Santoro N, Feldstein AE. The role of oxidized lipid species in insulin resistance and NASH in children. Front Endocrinol 2022;13:1019204. [DOI: 10.3389/fendo.2022.1019204] [Reference Citation Analysis]
32 Chan KE, Ng CH, Fu CE, Quek J, Kong G, Goh YJ, Zeng RW, Tseng M, Aggarwal M, Nah B, Chee D, Wong ZY, Zhang S, Wang JW, Chew NWS, Dan YY, Siddiqui MS, Noureddin M, Sanyal AJ, Muthiah M. The Spectrum and Impact of Metabolic Dysfunction in MAFLD: A Longitudinal Cohort Analysis of 32,683 Overweight and Obese Individuals. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00926-0. [PMID: 36202348 DOI: 10.1016/j.cgh.2022.09.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Tang A, Ng CH, Phang PH, Chan KE, Chin YH, Fu CE, Zeng RW, Xiao J, Tan DJH, Quek J, Lim WH, Mak LY, Wang JW, Chew NWS, Syn N, Huang DQ, Siddiqui MS, Sanyal A, Muthiah M, Noureddin M. Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00669-3. [PMID: 35863685 DOI: 10.1016/j.cgh.2022.06.029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]